October 23, 2024
1 min watch
Save
VIDEO: Phase 3 geographic atrophy program focuses on visual acuity
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Douglas Love, president and CEO of Annexon Biosciences, discusses the company’s phase 3 program in geographic atrophy.
According to Love, the primary endpoint of the program is visual acuity, “which in effect means we have slowed disease worsening in patients and allowed them to preserve their vision for longer.”
Annexon anticipates a data readout in 2026.
Published by:
Sources/Disclosures
Collapse
Source:
Love D. AAO 2024 retina showcase. Presented at: Eyecelerator@AAO; Oct. 17, 2024; Chicago.
Disclosures:
Love reports being president and CEO of Annexon Biosciences.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.